Abstract
Overall, the studies described in the present dissertation are aimed at the improvement of personalised medicine strategies for various types of cancer. The studies in parts 1 and 2 describe potential novel therapeutic avenues to treat IDH1/2-mutated cancers and the conditions in which they may have optimal effects. The studies described in part 3 may improve risk/benefit assessments for the application of cytotoxic therapies in an individual patient, and the follow-up after the administration of such cytotoxic therapies. These nuances may ultimately improve personalized treatment and management of cancer.
Original language | English |
---|---|
Qualification | Doctor of Philosophy |
Awarding Institution |
|
Supervisors/Advisors |
|
Award date | 22 Dec 2017 |
Print ISBNs | 978-94-6299-812-4 |
Publication status | Published - 2017 |
Externally published | Yes |